Chemistry:Amulirafusp alfa
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Human |
| Target | CD20, SIRPα |
| Identifiers | |
| CAS Number | |
| UNII | |
Amulirafusp alfa (IMM0306) is a cancer immunotherapy that targets CD20-positive B-cell malignancies. It is a fusion protein that combines a CD20 monoclonal antibody with the CD47 binding domain of SIRPα, allowing it to simultaneously engage both CD20 and CD47 on cancer cells.[1] Amulirafusp alfa has a dual mechanism of action that enhances both macrophage-mediated phagocytosis and natural killer cell activation.[2]
References
- ↑ "Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study". Journal of Hematology & Oncology 17 (1): 123. December 2024. doi:10.1186/s13045-024-01646-2. PMID 39696680.
- ↑ "839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.". Annals of Oncology 35: S610. September 2024. doi:10.1016/j.annonc.2024.08.890.
 |  |
